Centene Corp (CNC) carries a ŷRobot AI score of 76 out of 100. The model's fair value estimate is $75.46, 21.3% above the last close of $62.21. The chart signal reads Bullish.
| Metric | CNC |
|---|---|
| AI score | 76 / 100 |
| Chart signal | Bullish |
| Fair value estimate | $75.46 |
| Upside to fair value | 21.3% |
| Previous close | $62.21 |
| P/E | -6.26 |
| Price / sales | 0.18 |
| Market cap | $30.89B |
| EPS | -10.27 |
| Revenue growth | 9.7% |
| 1-year price change | 0.2% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Sep 29, 2026, ŷRobot's fair-value model estimates Centene Corp (CNC) at $75.46 against a last close of $62.21, implying 21.3% upside to the model's estimate.
The chart-signal model classifies CNC as Bullish as of Sep 29, 2026, with a signal score of 0.17 on a -1 to 1 scale.
CNC scores 76 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 29, 2026.
CNC trades at -6.3 times earnings and 0.2 times sales as of Sep 29, 2026.
ŷRobot's seasonal forecast curve for CNC reads +0.3% at 30 days, +1.8% at 90 days, and +0.2% at one year as of Sep 29, 2026. Seasonal tendencies are historical patterns, not predictions.
Centene Corp's revenue growth is +9.7% and free-cash-flow growth is +81.6% on the latest reported figures.
CNC chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.